fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Amiloride HCL & hydrochlorothiazide

All products: general benefit

AA-Amilzide · DIN 00784400 · 5 mg & 50 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
AA-Amilzide · DIN 00784400 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Daily cost (source): $0.0484 Health Canada: Marketed since 2019-10-30 · brand AA-AMILZIDE · ATC C03EA01 HYDROCHLOROTHIAZIDE AND POTASSIUM-SPARING AGENTS, C03EA01 HYDROCHLOROTHIAZIDE AND POTASSIUM-SPARING AGENTS · form Tablet · route Oral · ingredients AMILORIDE HYDROCHLORIDE 5 MG, HYDROCHLOROTHIAZIDE 50 MG · company Aa pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

AA-Amilzide: Formulary list price $0.10 per unit (the source does not state the unit; exact figure $0.0969). What the ministry pays, not the patient.

Ministry pays: $0.0969 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00784400)

Source record
DIN 00784400: AA-Amilzide Raw flags: chronicUseMed=Y, sec3=Y Item: 402800032; group id 556; item number 1494; lccId None; manufacturer id AAP Source form: Tab; strength: 5mg & 50mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.0969; ministry $0.0969 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00784400 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10494
Interchangeable products
Moduret · DIN 00487813 · not recorded
Shortage status: resolved shortage (ended July 10, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00784400
Shortage record checked October 6, 2026

Other products in the same Health Canada class (C03EA): coverage varies; not interchangeable

  • Hydrochlorothiazide + spironolactone (Aldactazide-25): general benefit, not a benefit
  • Hydrochlorothiazide + triamterene (Apo-Triazide): general benefit, not a benefit
Other drugs in the same formulary class (40:28 Diuretics) and how they are covered

Matched class: 40:28 Diuretics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMILORIDE HCL, METOLAZONE Some products covered without a code (check the product listing): CHLORTHALIDONE, FUROSEMIDE, HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE & SPIRONOLACTONE, HYDROCHLOROTHIAZIDE & TRIAMTERENE, INDAPAMIDE, SPIRONOLACTONE 40:28 Diuretics

HYDROCHLOROTHIAZIDE & SPIRONOLACTONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 25mg & 25mg, 50mg & 50mg · Tab

HYDROCHLOROTHIAZIDE & TRIAMTERENE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 25mg & 50mg · Tab

AMILORIDE HCL

· 1 products · General benefit · strengths: 5mg · Tab

CHLORTHALIDONE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 50mg · Tab

FUROSEMIDE

· 14 products · Limited Use, codes 481, 657 (2), General benefit (9), Listed, not a benefit (2), Limited Use, codes 33 (1) · strengths: 10mg/mL, 20mg, 40mg, 500mg · Inj Sol (Preservative Free), O/L, Tab

HYDROCHLOROTHIAZIDE

· 12 products · Off-Formulary Interchangeable, not an ODB benefit (3), Listed, not a benefit (2), General benefit (7) · strengths: 12.5mg, 25mg, 50mg · Tab

INDAPAMIDE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 1.25mg, 2.5mg · Tab

METOLAZONE

· 1 products · General benefit · strengths: 2.5mg · Tab

SPIRONOLACTONE

· 8 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (6) · strengths: 25mg, 100mg · Tab

MIDODRINE HCL

· 10 products · Listed, not a benefit (2), Limited Use, codes 01 (8) · strengths: 2.5mg, 5mg · Tab

TOLVAPTAN

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 15mg & 15mg, 30mg & 15mg, 45mg & 15mg, 60mg & 30mg, 90mg & 30mg · 14-Tabs Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 40:28
Full class listing Related classes: 40:12 Replacement Agents, 40:18 Potassium-Removing Resins, 40:40 Uricosuric Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS AA-AMILZIDE (amiloride hydrochloride and hydrochlorothiazide tablet) is indicated in the maintenance therapy of patients with: ▪ hepatic cirrhosis with ascites and edema. ▪ edema of cardiac origin or with arterial hypertension who are hypokalemic or in whom maintenance of normal potassium levels is considered to be clinically important i.e., digitalized patients, patients in whom adequate dietary intake of potassium is not feasible or patients with cardiac arrhythmias. Use in Hepatic Cirrhosis with Ascites and Edema Amiloride hydrochloride used alone may provide satisfactory diuresis with diminished potassium loss and with a reduced risk of metabolic alkalosis. In resistant cases amiloride hydrochloride may be used with kaliuretic-diuretic agents to help produce satisfactory diuresis, while maintaining a more balanced serum electrolyte pattern. As with all therapy for the ascites of hepatic cirrhosis, gradual weight loss and avoidance of electrolyte imbalance are the chief objectives (See 7 WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic). 1.1 Pediatrics Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada… https://pdf.hres.ca/dpd_pm/00069954.PDF PM date: MAR 13, 2019 Source product: AA-AMILZIDE; DIN 00784400; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.